Fig. 6.

Examination of the involvement of T cells and improvement in tumor microenvironment. A Flow cytometry quantification of ki67⁺ proliferative percentages of CD8⁺ and CD4⁺T cells in tumor tissue of prostate cancer mice treated with cisplatin, DEX_XCL1, cisplatin combined with DEX_XCL1 or PBS treated group (Negative control) (n = 4). B Representative flow cytometry quantification of intratumoral Granzyme-B⁺ CD8⁺ T cells from treated mice (n = 4). C Representative flow cytometry quantification of intratumoralFoxp3⁺ CD4⁺ T cells from treated mice (n = 4). D Quantification of cytokine -TGF-β and IFNγ in tumor homogenate from treated mice with ELISA (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001)